Get the Stockscreener App
18.25
5.88%
-1.14
After Hours:
18.40
0.15
+0.82%
Avalo Therapeutics Inc stock is traded at $18.25, with a volume of 895.23K.
It is down -5.88% in the last 24 hours and down -1.24% over the past month.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
See More
Previous Close:
$19.39
Open:
$19.5
24h Volume:
895.23K
Relative Volume:
0.47
Market Cap:
$965.48M
Revenue:
$59,000
Net Income/Loss:
$-84.74M
P/E Ratio:
-3.1346
EPS:
-5.8222
Net Cash Flow:
$-59.69M
1W Performance:
-1.03%
1M Performance:
-1.24%
6M Performance:
+20.78%
1Y Performance:
+131.31%
1-Day Range:
$18.24
$19.73
1-Week Range:
$18.24
$20.01
52-Week Range:
$7.5139
$24.27
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Name
Avalo Therapeutics Inc
Sector
Industry
Phone
410-522-8707
Address
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
18.25 | 1.03B | 59,000 | -84.74M | -59.69M | -5.8222 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Apr-06-26 | Initiated | Citizens | Mkt Outperform |
| Feb-02-26 | Initiated | Guggenheim | Buy |
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Sep-17-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-25 | Initiated | TD Cowen | Buy |
| Aug-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Mar-25-25 | Initiated | Jefferies | Buy |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-28-25 | Initiated | Piper Sandler | Overweight |
| Feb-21-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Oct-24-24 | Initiated | H.C. Wainwright | Neutral |
| Apr-16-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-24-21 | Initiated | RBC Capital Mkts | Outperform |
View All
Avalo Therapeutics Inc Stock (AVTX) Latest News
Avalo Therapeutics Inc (AVTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Avalo Therapeutics Inc (AVTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BlackRock Inc. (AVTX) discloses 6.5% Avalo Therapeutics stake on Schedule 13G - Stock Titan
AVTX|Avalo Therapeutics Inc|Price:19.915|Chg%:+1.475 - TradingKey
Avalo Therapeutics Inc (AVTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Avalo Therapeutics Inc (AVTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Avalo Therapeutics Inc (AVTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Avalo Therapeutics Inc Revenue Breakdown – TRADEGATE:C6K0 - TradingView
Avalo Therapeutics Inc (AVTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TradingKey - TradingKey
Avalo Therapeutics(AVTX) Stock Options Chain | Quotes & News - Moomoo
AVTX|Avalo Therapeutics Inc|Price:18.440|Chg%:+0.680 - TradingKey
Avalo Therapeutics Inc (AVTX) Balance Sheet - TradingKey
Avalo Therapeutics Inc (AVTX) Cash Flow - TradingKey
AVTX|Avalo Therapeutics Inc|Price:18.210|Chg%:+0.450 - TradingKey
Cantor Fitzgerald reiterates Avalo Therapeutics stock rating By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Avalo Therapeutics stock rating - Investing.com
Avalo Therapeutics Inc (AVTX) Institutional Confidence - TradingKey
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference - The Manila Times
Avalo CEO to Participate in Virtual Hidradenitis Panel July 29 - Stock Titan
Avalo Therapeutics Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Avalo Therapeutics Rings the Closing Bell - Nasdaq
Form S-3 Avalo Therapeutics Inc For: 17 July By Investing.com - Investing.com Nigeria
AVALO THERAPEUTICS INC (AVTX) Stock Chart - ChartMill
Avalo Therapeutics Says Some Shareholders May Sell Up to 128,189 Shares - Moomoo
Avalo Therapeutics (NASDAQ: AVTX) files to register 128,189 shares for selling stockholders - Stock Titan
(AVTX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum - The Manila Times
Millennium Group (AVTX) reports shared control of 9,857 Avalo shares (Jul 2026) - Stock Titan
AVTX Initiates Coverage by Leerink Partners -- Rating Set to Out - GuruFocus
Leerink initiates Avalo Therapeutics stock with outperform rating By Investing.com - Investing.com Australia
Leerink Partners Initiates Avalo Therapeutics(AVTX.US) With Buy Rating, Announces Target Price $38 - Moomoo
Leerink initiates Avalo Therapeutics stock with outperform rating - Investing.com
AVTX Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Market ReactionEarnings Beat Streak - dars.gov.et
Avalo Therapeutics CLO Paul Varki sells $1.5m shares after option exercise - Investing.com
Certain Restricted Stock Units of Avalo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 5-JUL-2026. - marketscreener.com
Certain Options of Avalo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 5-JUL-2026. - marketscreener.com
AVTXAvalo Therapeutics Inc Latest SEC Filings - Finviz
AVTX News | AVALO THERAPEUTICS INC (NASDAQ:AVTX) - ChartMill
Avalo Therapeutics (AVTX) director receives fully vested options grant - Stock Titan
Avalo Therapeutics (AVTX) CMO exercises options, sells 4,654 pre-planned shares - Stock Titan
Avalo Therapeutics (AVTX) director granted fully vested options on 1,080 shares - Stock Titan
Avalo Therapeutics (AVTX) director receives grant of 1,105 stock options - Stock Titan
Why Did AVTX Stock Surge 45% In Pre-Market Today? - Stocktwits
Price to earnings forward of Avalo Therapeutics, Inc. – NASDAQ:AVTX - TradingView
Enterprise value to revenue forward of Avalo Therapeutics, Inc. – NASDAQ:AVTX - TradingView
Price to sales forward of Avalo Therapeutics, Inc. – NASDAQ:AVTX - TradingView
Enterprise value to EBITDA forward of Avalo Therapeutics, Inc. – NASDAQ:AVTX - TradingView
Price to book forward of Avalo Therapeutics, Inc. – NASDAQ:AVTX - TradingView
Price to sales forward of Avalo Therapeutics Inc – LSX:A3E2FR - TradingView
Avalo Therapeutics (AVTX) Is Up 12.9% After Broad Russell Index AdditionsWhat's Changed - Yahoo Finance
Avalo Therapeutics Inc Stock (AVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avalo Therapeutics Inc Stock (AVTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Doyle Mittie | Chief Medical Officer |
Jun 23 '26 |
Sale |
18.00 |
1,450 |
26,100 |
51,776 |
2.44%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):